Pepcid and Nephrogenic systemic fibrosis - a phase IV clinical study of FDA data

Summary:

Nephrogenic systemic fibrosis is reported as a side effect among people who take Pepcid (famotidine), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Nephrogenic systemic fibrosis when taking Pepcid. It is created by eHealthMe based on reports of 54,527 people who have side effects when taking Pepcid from the FDA, and is updated regularly.

What is Pepcid?

Pepcid has active ingredients of famotidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 55,774 Pepcid users. Check the latest studies of Pepcid.

What is Nephrogenic systemic fibrosis?

Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease) is found to be associated with 510 drugs and 672 conditions by eHealthMe. Check the latest studies of Nephrogenic systemic fibrosis.

On Jul, 15, 2026

54,527 people reported to have side effects when taking Pepcid.
Among them, 51 people (0.09%) have Nephrogenic systemic fibrosis.

Could Pepcid cause Nephrogenic systemic fibrosis?

Among these 51 people:

How long have people been on Pepcid when they have Nephrogenic systemic fibrosis? *

What is the gender of people who have Nephrogenic systemic fibrosis when taking Pepcid? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Nephrogenic systemic fibrosis when taking Pepcid? *

What are other drugs people take besides Pepcid? *

What are other side effects people have besides Nephrogenic systemic fibrosis? *

Skin Tightness: 35 people, 68.63%
Skin Hypertrophy (skin cells enlarges): 30 people, 58.82%
Joint Range Of Motion Decreased (disease of joint movement): 29 people, 56.86%
Oedema Peripheral (superficial swelling): 29 people, 56.86%
Pain: 27 people, 52.94%
Skin Induration (an abnormally hard spot or area on the skin): 27 people, 52.94%
Rashes (redness): 22 people, 43.14%
Itching: 21 people, 41.18%
Mobility Decreased (ability to move is reduced): 20 people, 39.22%
Skin Exfoliation (removal of the oldest dead skin cells): 20 people, 39.22%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 25 people, 49.02%
Pain: 11 people, 21.57%
Nuclear Magnetic Resonance Imaging Abdominal: 6 people, 11.76%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 5 people, 9.80%
Rash Pruritic (redness with itching): 3 people, 5.88%
Tumor: 2 people, 3.92%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 2 people, 3.92%
Constipation: 2 people, 3.92%
Stress And Anxiety: 2 people, 3.92%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 3.92%

* Approximation only. Some reports may have incomplete information.

Do you take Pepcid and have Nephrogenic systemic fibrosis?

- Check whether Nephrogenic systemic fibrosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pepcid:

Pepcid (55,774 reports)

Browse all side effects of Pepcid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (510 drugs)

Browse all the conditions that are associated with Nephrogenic systemic fibrosis:

Nephrogenic systemic fibrosis (672 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on famotidine (the active ingredients of Pepcid) and Pepcid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.